SCHEDULE 13G/A 0000902664-24-005996 0000919185 XXXXXXXX LIVE 1 Common Stock, par value $0.001 per share 06/30/2025 0001711754 Inmune Bio, Inc. 45782T105 225 NE MIZNER BLVD, SUITE 640 BOCA RATON FL 33432 Rule 13d-1(b) Highbridge Capital Management, LLC DE 1454400.00 0.00 1454400.00 0.00 1454400.00 N 5.2 IA OO The 1,454,400 shares of Common Stock (as defined in Item 2(a)) reported herein are issuable upon exercise of warrants. Inmune Bio, Inc. 225 NE Mizner Blvd, Suite 640, Boca Raton, FL, 33432 This statement is filed by Highbridge Capital Management, LLC ("Highbridge" or the "Reporting Person"), a Delaware limited liability company and the investment adviser to certain funds and accounts (the "Highbridge Funds"), with respect to the shares of common stock, par value $0.001 per share (the "Common Stock") of Inmune Bio, Inc., a Nevada corporation (the "Issuer"), issuable upon exercise of warrants directly held by the Highbridge Funds. The filing of this statement should not be construed as an admission that any of the foregoing persons or the Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, the beneficial owner of the securities reported herein. The address of the business office of the Reporting Person is 277 Park Avenue, 23rd Floor, New York, New York 10172. Highbridge is a Delaware limited liability company. N IA The information required by Item 4(a) is set forth in Row 9 of the cover page for the Reporting Person and is incorporated herein by reference. The percentage set forth in this Schedule 13G is calculated based upon an aggregate of 26,585,258 shares of Common Stock outstanding as of June 30, 2025, as reported in the Issuer's Prospectus filed pursuant to Rule 424(b)(5) with the Securities and Exchange Commission on June 30, 2025, after giving effect to the completion of the offering as described therein, and assumes the exercise of the warrants held by the Highbridge Funds. 5.2% The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for the Reporting Person and is incorporated herein by reference. The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for the Reporting Person and is incorporated herein by reference. The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for the Reporting Person and is incorporated herein by reference. The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for the Reporting Person and is incorporated herein by reference. Y N See Item 2(a). The Highbridge Funds have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of Common Stock reported herein. Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Highbridge Capital Management, LLC /s/ Kirk Rule 08/14/2025